This is a phase II trial using a non-myeloablative cyclophosphamide/ fludarabine/total body
irradiation (TBI) preparative regimen followed by a related or unrelated donor stem cell
infusion. The primary objective is to evaluate rates of acute graft-versus-host disease
(GVHD) grades II-IV and chronic GVHD with an updated GVHD prophylaxis of tacrolimus and
mycophenolate mofetil (MMF) with a non-myeloablative preparative regimen in persons with
Peripheral Blood Stem Cells,
Related or Unrelated Bone Marrow Cells
Clinical Study Identifier
Masonic Cancer Center, University of Minnesota
Last Modified on
8 October 2020
How clear was the trial content above?
Adding a note
Select a piece of text and start making personal notes.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.